Arbutus Biopharma (ABUS) vs Rigel Pharmaceuticals (RIGL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Rigel Pharmaceuticals (RIGL) has outperformed Arbutus Biopharma (ABUS) over the past year, gaining 62.7% versus a gain of 0.0%. Over five years, RIGL leads with a +42.0% price change compared with +5.1% for ABUS. Rigel Pharmaceuticals is the larger company by market cap ($896.4 million vs $657.6 million), about 1.4 times the size.
On valuation, Rigel Pharmaceuticals trades at a lower trailing P/E (2.8x vs 5.4x for Arbutus Biopharma).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABUS | RIGL |
|---|---|---|
| Share price | $4.29 | $47.99 |
| Market cap | $657.55M | $896.45M |
| 1-day change | -4.24% | +4.08% |
| YTD return | -10.81% | +12.05% |
| 1-year return | 0.00% | +62.68% |
| 5-year return | +5.15% | +41.98% |
| P/E ratio (TTM) | 5.43 | 2.84 |
| Forward P/E | — | 9.72 |
| EPS (TTM) | $0.79 | $16.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.45 | $52.24 |
| 52-week low | $3.50 | $24.95 |
| Distance from 52-week high | -21.28% | -8.14% |
| Average volume | 4.65M | 291.93K |
| Shares outstanding | 153.28M | 18.68M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RIGL has outperformed ABUS by 62.7 percentage points over the past year.
- Arbutus Biopharma trades at a higher earnings multiple (5.4x vs 2.8x trailing P/E).
ABUS vs RIGL FAQ
Which is bigger, Arbutus Biopharma or Rigel Pharmaceuticals?
Rigel Pharmaceuticals (RIGL) is larger, with a market capitalization of $896.45M compared with $657.55M for Arbutus Biopharma (ABUS).
Which stock has performed better over the past year, ABUS or RIGL?
RIGL returned +62.68% over the past 12 months, compared with 0.00% for ABUS (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ABUS or RIGL?
RIGL has the lower trailing P/E at 2.8, versus 5.4 for ABUS. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Arbutus Biopharma and Rigel Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.